Physician profile
Craig Recko
NPI 1578783486
$6,649.69
in general payments reported to CMS, 2019-2025
42 companies · $14.82 in 2025
The $14.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $1,430 · 2021: $1,384 · 2022: $1,327 · 2023: $712 · 2024: $13.75 · 2025: $14.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $765.20 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $708.65 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.40 | 2019-2023 | Jardiance, Ofev, Spiriva Respimat |
| Amgen INC. | $396.01 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $309.73 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $275.84 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $254.98 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.61 | 2019-2023 | Trulance, Xifaxan |
| Allergan, INC. | $237.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.94 | 2019-2022 | |
| Astellas Pharma US INC | $213.66 | 2019-2023 | Myrbetriq |
| Lilly USA, LLC | $175.02 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $171.87 | 2019-2021 | |
| Eisai INC. | $159.62 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Recko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.